Clinical Trials Browser

Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

1,460 enrolled

Breast

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Tumor-Agnostic

Neoplasms

NCT02451956 2019-12-30

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Phase 2 Completed

21 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

1,150 enrolled

Breast

Advanced Breast Cancer

NCT02077569 2017-05-04

STAKT

Phase 2 Completed

48 enrolled

Breast

Breast Neoplasms

Clinical Trials

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

CaptAin

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

PAKT

SAFIR02_Breast

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

SAFIR02_Lung

OLAPCO

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

plasmaMATCH

STAKT